In addition to the upfront fee, Servier has committed up to $1.1 billion in regulatory and commercial milestones to acquire ...

The companies anticipate finalising the acquisition in the third quarter of 2026.

The purpose of this report is to re-evaluate such a therapeutic program in muscular dystrophy when the drugs are used singly, in combination and with or without exercise. Objective serial measurements ...

Myotonic dystrophy type 1 (DM1) is a genetic disease characterized by progressive muscular weakness. There is currently no treatment despite many recent efforts. But now researchers from Japan may ...

Edgewise Therapeutics (EWTX) stays a Buy after its $2.65B Servier deal funds EDG-7500 for HCM with key Q2 2026 data. Read ...

Nine people around the world who have been living with unexplained, muscular dystrophy-like symptoms may now have an answer for what is causing the progressive muscle weakness in their body's ...

June 1 (Reuters) - Biotech firm Edgewise Therapeutics said on Monday it would sell its experimental muscular dystrophy drug and related business to France's Servier for up to $2.65 billion. The French ...

Under the agreement, Servier will pay $1.55 billion upfront, with up to an additional $1.1 billion tied to regulatory and ...

The most commonly diagnosed form of muscular dystrophy, Duchenne is a genetic disease that affects mostly boys and causes progressive muscle weakness over time. Its early physical signs tend to be ...

This study was carried out on 9 patients with myotonic dystrophy and 8 with slowly progressive nonmyotonic muscular dystrophy admitted to the Neurology Service at Duke University Hospital and the ...

Orphan Drug Designation (ODD) recognizes Duchenne muscular dystrophy as a rare disease with significant unmet medical need without an established ...

DR. JULIA BELL has contributed a useful monograph on muscular dystrophy in man to “The Treasury of Human Inheritance” series. Clinical and genetical data from more than 1,300 individuals exhibiting ...